Priscilla Driscoll-Shempp

TL;DR: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.

TL;DR: Continuing thienopyridine for an additional 18 months compared with placebo did not result in statistically significant differences in rates of stent thrombosis, MACCE, or moderate or severe bleeding, but the BMS subset may have been underpowered to identify such differences, and further trials are suggested.

TL;DR: DES- treated subjects have long-term rates of stent thrombosis that are lower than BMS-treated subjects, and these rates are higher than previously reported in dual antiplatelet therapy duration studies.

TL;DR: Although trial participants were representative of PCI patients with respect to race, sex and most comorbidities, they had a lower prevalence of chronic cardiovascular disease compared with registry patients, suggesting a streamlined cardiovascular clinical trial may successfully involve a large number of hospitals and rapidly enroll a diverse population of patients.